A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza

Recruiting

Phase 3

CD388A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza

Sponsor:

Cidara Therapeutics Inc.

Code:

NCT07159763

Conditions

Influenza

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

CD388 Injection

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-29. This information was provided to ClinicalTrials.gov by Cidara Therapeutics Inc. on 2025-10-27.